Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar

 Financing, Special Reports, and Clinical Trial Updates - Research Report on
                 PDL, DexCom, Quintiles, KYTHERA, and Nektar

PR Newswire

NEW YORK, November 20, 2013

NEW YORK, November 20, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting PDL
BioPharma, Inc. (NASDAQ: PDLI), DexCom, Inc. (NASDAQ: DXCM), Quintiles
Transnational Holdings, Inc. (NYSE: Q), KYTHERA Biopharmaceuticals, Inc.
(NASDAQ: KYTH), and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

PDL BioPharma, Inc. Research Report

On November 6, 2013, PDL BioPharma, Inc. (PDL) announced that it has closed a
financing transaction with Durata Therapeutics, Inc. (Durata).Under the credit
agreement, PDL will provide Durata with up to $70 million of debt financing
with a five-year term and will receive interest on the principal amount
outstanding and a security interest in substantially all of Durata's assets.
"We are pleased to provide this non-dilutive financing to Durata. Based upon
our extensive due diligence, we believe that dalbavancin will be a medically
and commercially significant product," said John P. McLaughlin, President and
CEO of PDL. "This deal with Durata marks the fourth transaction we have closed
in recent weeks and, in doing so, we believe that we are securing measurable
value for PDL and our stockholders." The Full Research Report on PDL
BioPharma, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/066b_PDLI

DexCom, Inc. Research Report

On November 6, 2013, DexCom, Inc. (DexCom) announced that it has appointed
Steve Altman as an independent Board member of the Company. According to
DexCom, Altman is currently the Vice Chairman of Qualcomm Incorporated
(Qualcomm) and has served on its executive committee for almost 15 years. "We
are thrilled to announce Steve's addition to the Board," said Terry Gregg, CEO
of DexCom. "Steve is an incredibly skilled, passionate and visionary business
leader who will bring a unique and important perspective to our Board. His
experience in directing Qualcomm's growth will be invaluable as we continue to
design and execute our own growth strategy. We welcome Steve to our Board of
Directors." The Full Research Report on DexCom, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/d377_DXCM

Quintiles Transnational Holdings, Inc. Research Report

On November 14, 2013, Quintiles Transnational Holdings, Inc. (Quintiles)
announced that it has published its perspectives on diabetes drug development
with a special report on development for pediatric indications, in relation to
World Diabetes Day. The Company noted that the report addresses specific
clinical, design, and operational considerations for pediatric diabetes
clinical trials. According to Quintiles, the report also concludes that the
disease burden is high, with a large unmet need for new diabetes therapies in
the pediatric population. Further, the report provides information to assist
in the planning of pediatric studies aimed at making more treatment options
available to children. "Whether our sponsors grapple with the challenge of
designing trials in a renally-impaired diabetic population or are creating an
insulin algorithm for a type one diabetes population, they turn to Quintiles
for our extensive experience in clinical research," said Erica Caveney, M.D.,
Senior Director and Global Diabetes Therapeutic Strategy Head of
Cardiovascular and Metabolic Therapeutic Delivery Unit at Quintiles. The Full
Research Report on Quintiles Transnational Holdings, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/9f5c_Q

KYTHERA Biopharmaceuticals, Inc. Research Report

On November 14, 2013, KYTHERA Biopharmaceuticals, Inc. (KYTHERA) reported Q3
2013 financial results. In Q3 2013, the Company recorded net loss of $11.5
million, or $0.62 loss per basic and diluted share, compared with net loss of
$16.4 million, or $11.41 loss per basic and diluted share, in Q3 2012. "We are
very pleased with the recent positive results from our pivotal Phase III
clinical trials that demonstrate the ability of ATX-101 to reduce fat under
the chin and improve the patient's submental profile. We are now focused on
the preparation and filing of our New Drug Application, which we expect to
occur in the second quarter of 2014," said Keith Leonard, President and CEO of
KYTHERA. "We believe these positive results, coupled with our strong balance
sheet as a result of our recently closed public offering, position us well to
execute on our business objectives." The Full Research Report on KYTHERA
Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b90a_KYTH

Nektar Therapeutics Research Report

On November 13, 2013, Nektar Therapeutics (Nektar) reported that Baxter
International Inc. (Baxter) has completed enrollment in its Phase III clinical
trial of BAX 855, an investigational extended half-life, recombinant factor
VIII treatment for hemophilia A, and employs proprietary PEGylation technology
from Nektar to extend duration of activity of proteins. Nektar further
reported that Baxter expects to complete the trial and file for regulatory
approval in late 2014. "The BAX 855 development program is a priority for
Baxter as we evaluate the potential to provide an efficacious and safe
treatment with an extended half-life for patients with hemophilia," said
Anders Ullman, M.D., Ph.D., Vice President of Global Research and Development
in Baxter's BioScience business. "We are focused first and foremost on
strategies to address optimal efficacy and minimize patients' bleeding
episodes, while at the same time delivering on the convenience of less
frequent dosing for this population with severe disease." The Full Research
Report on Nektar Therapeutics - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3421_NKTR

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.